|Array BioPharma & AstraZeneca||ARRY-704 (AZD8330)||Oncology - undisclosed but preclinical studies in melanoma, pancreatic, colon, lung, and breast cancers||MEK inhibitor - MEK regulates cell proliferation and survival as part of the Ras/Raf/MEK/ERK pathway.|
|Poniard Pharmaceuticals||Oral picoplatin||Oncology - various solid tumours||Cytotoxic platinum compound - causes cell death by binding to DNA and interfering with DNA replication and transcription N.B. other Phase I & II clinical trials for intravenous formulation|
|Kalypsys||KD7040||Neuropathic pain||Topical inducible nitric oxide synthase (iNOS) inhibitor|
|Hadasit Bio-Holdings & Verto||Lupusorb||Autoimmune - Lupus||Device with specific peptide (VRT101 - from C terminal of laminin) to remove disease-causing auto-antibodies from the blood during plasmapheresis. N.B. Combined Phase I/II trial|
|Addex Pharmaceuticals||ADX48621||CNS - primarily depression but also potentially generalised anxiety disorder and inflammatory pain||Negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5)|
The eleventh in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.